Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · see citing works

Blinded by the Light: The Growing Complexity of p53

Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · see citing works

Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations

Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559 · see citing works

DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2

Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · see citing works

Tumor spectrum analysis in p53-mutant mice

Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051 · see citing works

The first 30 years of p53: growing ever more complex.

Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · see citing works

The p53 pathway: positive and negative feedback loops

Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967 · see citing works

p53 mutations in cancer

Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647 · see citing works

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · see citing works

Clinical Implications of the p53 Tumor-Suppressor Gene

Harris, C. C., & Hollstein, M. C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,317 · see citing works

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · see citing works

MDM2, MDMX and p53 in oncogenesis and cancer therapy

Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · see citing works

Mutant p53: one name, many proteinsPreprint

Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,246 · see citing works

Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome

Srivastava, S. K., Zou, Z., Pirollo, K. F., Blattner, W. A., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,210 · see citing works

When mutants gain new powers: News from the mutant p53 field

Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · see citing works

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · see citing works

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works

p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,065 · see citing works

p53 ubiquitination: Mdm2 and beyond

Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924 · see citing works

Gain of function mutations in p53

Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894 · see citing works

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · see citing works

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865 · see citing works

A chromatin remodelling complex involved in transcription and DNA processing

Shen, X., Mizuguchi, G., Hamiche, A., & Wu, C. (2000) · Nature · doi:10.1038/35020123 · Cited by 807 · see citing works

Mutant p53 drives invasion by promoting integrin recycling

Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796 · see citing works

Mutant p53 Gain-of-Function in CancerPreprint

Oren, M., & Rotter, V. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753 · see citing works

Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation

Brooks, C. L., & Gu, W. J. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00003-6 · Cited by 742 · see citing works

Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation

Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., & Rotter, V. (1984) · Nature · doi:10.1038/312649a0 · Cited by 731 · see citing works

Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation

Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., & Benchimol, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00193-4 · Cited by 717 · see citing works

Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

Eliyahu, D., Raz, A., Gruß, P., Givol, D., & Oren, M. (1984) · Nature · doi:10.1038/312646a0 · Cited by 706 · see citing works

The ubiquitin ligase COP1 is a critical negative regulator of p53

Dornan, D., Wertz, I. E., Shimizu, H., Arnott, D. P., Frantz, G. D., Dowd, P., Rourke, K. O., Koeppen, H., & Dixit, V. M. (2004) · Nature · doi:10.1038/nature02514 · Cited by 700 · see citing works

Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 669 · see citing works

The P53 pathway: what questions remain to be explored?

Levine, A. J., Hu, W., & Feng, Z. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401910 · Cited by 654 · see citing works

Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation

Milner, J., & Medcalf, E. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612 · see citing works

Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.

Bártek, J., Iggo, R. D., Gannon, J., & Lane, D. P. (1990) · PubMed · Cited by 603 · see citing works

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J. C. S., Klaar, S., Eyfjord, J. E., Theillet, C. G., Rodríguez, C., Lidereau, R., Bièche, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 590 · see citing works

Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Chehab, N. H., Malikzay, A., Stavridi, E. S., & Halazonetis, T. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13777 · Cited by 583 · see citing works

Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53

Jenkins, J. R., Rudge, K., & Currie, G. A. (1984) · Nature · doi:10.1038/312651a0 · Cited by 538 · see citing works

p53 post-translational modification: deregulated in tumorigenesis

Dai, C., & Gu, W. J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.002 · Cited by 523 · see citing works

FAM/USP9x, a Deubiquitinating Enzyme Essential for TGFβ Signaling, Controls Smad4 Monoubiquitination

Dupont, S., Mamidi, A., Cordenonsi, M., Montagner, M., Zacchigna, L., Adorno, M., Martello, G., Stinchfield, M. J., Soligo, S., Morsut, L., et al. (2009) · Cell · doi:10.1016/j.cell.2008.10.051 · Cited by 494 · see citing works

Posttranslational Modification of p53: Cooperative Integrators of FunctionPreprint

Meek, D. W., & Anderson, C. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000950 · Cited by 487 · see citing works

A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain

Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464 · see citing works

Tumour-associated mutant p53 drives the Warburg effect

Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434 · see citing works

Chaperones in control of protein disaggregation

Liberek, K., Lewandowska, A., & Ziętkiewicz, S. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601970 · Cited by 425 · see citing works

Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation

Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418 · see citing works

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · see citing works

Molecular chaperone targeting and regulation by BAG family proteins

Takayama, S.-I. J., & Reed, J. C. (2001) · Nature Cell Biology · doi:10.1038/ncb1001-e237 · Cited by 400 · see citing works

COP9 signalosome‐specific phosphorylation targets p53 to degradation by the ubiquitin system

Bech‐Otschir, D., Kraft, R., Huang, X., Henklein, P., Kapelari, B., Pollmann, C., & Dubiel, W. (2001) · The EMBO Journal · doi:10.1093/emboj/20.7.1630 · Cited by 396 · see citing works

The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein

Feng, Z., & Levine, A. J. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.03.004 · Cited by 359 · see citing works

The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a lossPreprint

Terzian, T., Suh, Y., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Pelt, C. S. V., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 356 · see citing works

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz‐Heddergott, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 354 · see citing works

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336 · see citing works

Aurora-A Abrogation of p53 DNA Binding and Transactivation Activity by Phosphorylation of Serine 215

Liu, Q., Kaneko, S., Yang, L., Feldman, R. I., Nicosia, S. V., Chen, J., & Cheng, J. Q. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406802200 · Cited by 335 · see citing works

Allele-Specific p53 Mutant Reactivation

Yu, X., Vázquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 320 · see citing works

Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

Blagosklonny, M. V., Toretsky, J. A., Bohen, S. P., & Neckers, L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8379 · Cited by 315 · see citing works

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding

MIDGLEY, C. A., & Lane, D. P. (1997) · Oncogene · doi:10.1038/sj.onc.1201459 · Cited by 313 · see citing works

The BAG proteins: a ubiquitous family of chaperone regulators

Kabbage, M., & Dickman, M. B. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7535-2 · Cited by 308 · see citing works

Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

Li, D., Marchenko, N. D., Schulz‐Heddergott, R., Fischer, V., Velasco-Hernández, T., Talos, F., & Moll, U. M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0534 · Cited by 298 · see citing works

The Origins and Evolution of the p53 Family of GenesPreprint

Белый, В. А., Ak, P., Markert, E. K., Wang, H., Hu, W., Puzio‐Kuter, A. M., & Levine, A. J. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001198 · Cited by 293 · see citing works

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

Hanel, W. G., Marchenko, N. D., Xu, S., Yu, S., Weng, W., & Moll, U. M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.17 · Cited by 278 · see citing works

Induction and down-regulation of PLK, a humanserine/threonine kinase expressed in proliferating cells andtumors.

Holtrich, U., Wolf, G., Bräuninger, A., Karn, T., Böhme, B., Rübsamen‐Waigmann, H., & Strebhardt, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1736 · Cited by 276 · see citing works

Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer

Sigalas, I., Calvert, A. H., Anderson, J. J., Neal, D. E., & Lunec, J. (1996) · Nature Medicine · doi:10.1038/nm0896-912 · Cited by 268 · see citing works

Tumor suppressor p53 and its mutants in cancer metabolism

Liu, J., Zhang, C., Hu, W., & Feng, Z. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.025 · Cited by 266 · see citing works

Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation

Ando, K., Ozaki, T., Yamamoto, H., Furuya, K., Hosoda, M., Hayashi, S., Fukuzawa, M., & Nakagawara, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314182200 · Cited by 262 · see citing works

Protein rescue from aggregates by powerful molecular chaperone machines

Doyle, S. M., Genest, O., & Wickner, S. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3660 · Cited by 250 · see citing works

Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53

Stambolsky, P., Tabach, Y., Fontemaggi, G., Weisz, L., Maor-Aloni, R., Sigfried, Z., Shiff, I., Kogan, I., Shay, M., Kalo, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.025 · Cited by 245 · see citing works

Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1

Sampath, J., Sun, D., Kidd, V. J., Grenet, J., Gandhi, A., Shapiro, L. H., Wang, Q., Zambetti, G. P., & Schuetz, J. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103429200 · Cited by 244 · see citing works

Tumor Suppressor p53: Analysis of Wild-Type and Mutant p53 Complexes

Milner, J., Medcalf, E., & Cook, A. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.12 · Cited by 243 · see citing works

TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.

Olivier, M., Hussain, S. P., de Fromentel, C. C., Hainaut, P. L., & Harris, C. C. (2004) · PubMed · Cited by 243 · see citing works

Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer

Walerych, D., Lisek, K., Sommaggio, R., Piazza, S., Ciani, Y., Dalla, E., Rajkowska, K., Gaweda-Walerych, K., Ingallina, E., Tonelli, C., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3380 · Cited by 239 · see citing works

Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families

Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230 · see citing works

Ubiquitination and Degradation of Mutant p53

Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223 · see citing works

The Physical Association of Multiple Molecular Chaperone Proteins with Mutant p53 Is Altered by Geldanamycin, an hsp90-Binding Agent

Whitesell, L. J., Sutphin, P. D., Pulcini, E. J., Martinez, J. D., & Cook, P. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1517 · Cited by 206 · see citing works

Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage

Pratt, W. B., Morishima, Y., Peng, H., & Osawa, Y. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2009.009250 · Cited by 201 · see citing works

Alternative and aberrant splicing of MDM2 mRNA in human cancer

Bartel, F., Taubert, H. W., & Harris, L. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00091-0 · Cited by 196 · see citing works

LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers

Yu, H., Yue, X., Zhao, Y., Li, X., Wu, L., Zhang, C., Liu, Z., Lin, K., Xu-Monette, Z. Y., Young, K. H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6218 · Cited by 193 · see citing works

Chaperone-dependent stabilization and degradation of p53 mutants

Müller, P., Hrstka, R., Coomber, D., Lane, D. P., & Vojtěšek, B. (2008) · Oncogene · doi:10.1038/sj.onc.1211010 · Cited by 183 · see citing works

Inhibition of MDM2 by hsp90 Contributes to Mutant p53 Stabilization

Peng, Y., Chen, L., Li, C., Lu, W., & Chen, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102817200 · Cited by 180 · see citing works

The Regulation of Multiple p53 Stress Responses is Mediated through MDM2

Hu, W., Feng, Z., & Levine, A. J. (2012) · Genes & Cancer · doi:10.1177/1947601912454734 · Cited by 176 · see citing works

Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?

Li, Y., & Prives, C. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210311 · Cited by 174 · see citing works

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170 · see citing works

Interaction of p53 with the CCT Complex Promotes Protein Folding and Wild-Type p53 Activity

Trinidad, A. G., Muller, P. A. J., Cuéllar, J., Klejnot, M., Nobis, M., Valpuesta, J., & Vousden, K. H. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.05.002 · Cited by 147 · see citing works

Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cellsPreprint

Pfister, N. T., Fomin, V., Regunath, K., Zhou, J. Y., Zhou, W., Silwal‐Pandit, L., Freed-Pastor, W. A., Laptenko, O., Neo, S. P., Bargonetti, J., et al. (2015) · Genes & Development · doi:10.1101/gad.263202.115 · Cited by 143 · see citing works

E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis

Liu, J., Zhang, C., Wang, X. L., Ly, P., Белый, В. А., Xu-Monette, Z. Y., Young, K. H., Hu, W., & Feng, Z. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.121 · Cited by 137 · see citing works

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy

Bykov, V. J. N., Zhang, Q., Zhang, M., Ceder, S., Abrahmsen, L., & Wiman, K. G. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00021 · Cited by 137 · see citing works

Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.

Lukáš, J., Gao, D. Q., Keshmeshian, M., Wen, W., Tsao-Wei, D. D., Rosenberg, S. A., & Press, M. F. (2001) · PubMed · Cited by 133 · see citing works

Multiple Stress Signals Activate Mutant p53 In Vivo

Suh, Y., Post, S. M., Elizondo-Fraire, A. C., Macció, D. R., Jackson, J. G., El‐Naggar, A. K., Pelt, C. V., Terzian, T., & Lozano, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0459 · Cited by 119 · see citing works

Dietary downregulation of mutant p53 levels via glucose restriction

Rodriguez, O. C., Choudhury, S., Kolukula, V. K., Vietsch, E. E., Catania, J., Preet, A., Reynoso, K., Bargonetti, J., Wellstein, A., Albanese, C., et al. (2012) · Cell Cycle · doi:10.4161/cc.22778 · Cited by 114 · see citing works

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

Ramalingam, S. S., Goss, G. D., Rosell, R., Schmid‐Bindert, G., Zarić, B., Andric, Z. G., Bondarenko, I., Комов, Д. В., Cerić, T., Khuri, F. R., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv220 · Cited by 110 · see citing works

Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise

Proia, D. A., & Bates, R. C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3263 · Cited by 110 · see citing works

Prognostic significance of p53 gene alterations in node-negative breast cancer

Elledge, R. M., Fuqua, S. A. W., Clark, G. M., Pujol, P., Allred, D. C., & McGuire, W. L. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665800 · Cited by 110 · see citing works

Functional interplay between MDM2, p63/p73 and mutant p53

Stindt, M., Muller, P. A. J., Ludwig, R., Kehrloesser, S., Dötsch, V., & Vousden, K. H. (2014) · Oncogene · doi:10.1038/onc.2014.359 · Cited by 109 · see citing works

Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis

Zheng, T., Wang, J., Zhao, Y., Zhang, C., Lin, M., Wang, X., Yu, H., Liu, L., Feng, Z., & Hu, W. (2013) · Nature Communications · doi:10.1038/ncomms3996 · Cited by 108 · see citing works

A comparison between p53 accumulation determined by immunohistochemistry andTP53mutations as prognostic variables in tumours from breast cancer patients

Alsner, J., Jensen, V., Kyndi, M., Offersen, B. V., Vu, P., Børresen‐Dale, A., & Overgaard, J. (2008) · Acta Oncologica · doi:10.1080/02841860802047411 · Cited by 107 · see citing works

Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease

Shrestha, L., Bolaender, A., Patel, H., & Taldone, T. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160413141911 · Cited by 105 · see citing works

A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer

Jhaveri, K. L., Chandarlapaty, S., Lake, D. E., et al. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.12.012 · Cited by 104 · see citing works

The Role of p53 Gene Family in ReproductionPreprint

Hu, W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001073 · Cited by 100 · see citing works

Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms.

Matsumoto, R., Tada, M., Nozaki, M., Zhang, C. L., Sawamura, Y., & Abe, H. (1998) · PubMed · Cited by 97 · see citing works

Distinct pattern of p53 phosphorylation in human tumors

Minamoto, T., Buschmann, T., Habelhah, H., Matusevich, E., Tahara, H., Børresen‐Dale, A., Harris, C. C., Sidransky, D., & Ronai, Z. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204458 · Cited by 96 · see citing works

Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation

Gurpinar, E., & Vousden, K. H. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.04.001 · Cited by 94 · see citing works

Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells

Yi, Y. W., Kang, H. J., Kim, H. J., Kong, Y., Brown, M. L., & Bae, I. (2013) · Oncotarget · doi:10.18632/oncotarget.1070 · Cited by 93 · see citing works

Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells

Gu, H.-Y., Wang, X., Rao, S., Wang, J., Zhao, J., Ren, F. L., Mu, R., Yang, Y., Qi, Q., Liu, W., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0212 · Cited by 84 · see citing works

Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer

Blanden, A. R., Yu, X., Loh, S. N., Levine, A. J., & Carpizo, D. R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.006 · Cited by 83 · see citing works

BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function

Yue, X., Zhao, Y., Liu, J., Zhang, C., Yu, H., Wang, J., Zheng, T., Liu, L., Li, J., Feng, Z., et al. (2015) · eLife · doi:10.7554/elife.08401 · Cited by 81 · see citing works

Mutant TP53 Posttranslational Modifications: Challenges and Opportunities

Nguyen, T., Menéndez, D., Resnick, M. A., & Anderson, C. W. (2014) · Human Mutation · doi:10.1002/humu.22506 · Cited by 74 · see citing works

Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck.

González, M. V., Pello, M. F., López‐Larrea, C., Suarez, C. M., Menéndez, M., & Coto, E. (1995) · PubMed · Cited by 73 · see citing works

Targeting Mutant p53 in Human Tumors

Lehmann, B. D., & Pietenpol, J. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.0412 · Cited by 72 · see citing works

Mutant p53 Regulates Dicer through p63-dependent and -independent Mechanisms to Promote an Invasive Phenotype

Muller, P. A. J., Trinidad, A. G., Caswell, P. T., Norman, J. C., & Vousden, K. H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.502138 · Cited by 71 · see citing works

Tumor Suppressor p53: Analysis of Wild-Type and Mutant p53 Complexes

Milner, J., Medcalf, E., & Cook, A. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.12-19.1991 · Cited by 71 · see citing works

PML enhances the regulation of p53 by CK1 in response to DNA damage

Alsheich-Bartok, O., Haupt, S., Snir-Alkalay, I., Saito, S., Appella, E., & Haupt, Y. (2008) · Oncogene · doi:10.1038/sj.onc.1211036 · Cited by 69 · see citing works

Not all p53 gain-of-function mutants are created equal

Mello, S. S., & Attardi, L. D. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.53 · Cited by 69 · see citing works

SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma

Zhang, Z., Hong, D.-P., Nam, S. H., Kim, J. M., Paik, Y. H., Joh, J., Kwon, C. H. D., Park, J. B., Choi, G., Jang, K. Y., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.007 · Cited by 68 · see citing works

Gambogic acid‐induced degradation of mutant p53 is mediated by proteasome and related to CHIP

Wang, J., Zhao, Q. J., Qi, Q., Gu, H.-Y., Rong, J., Mu, R., Zou, M., Tao, L., You, Q., & Guo, Q. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22941 · Cited by 67 · see citing works

Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop

Valenti, F., Fausti, F., Biagioni, F., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18682 · Cited by 65 · see citing works

Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing

Will, K., Warnecke, G., Wiesmüller, L., & Deppert, W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13681 · Cited by 61 · see citing works

Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53

Haupt, S., Agostino, S. D., Mizrahi, I., Alsheich-Bartok, O., Voorhoeve, M., Damalas, A., Blandino, G., & Haupt, Y. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4010 · Cited by 59 · see citing works

Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase

Melnikova, V. O., Santamaria, A. B., Bolshakov, S. V., & Ananthaswamy, H. N. (2003) · Oncogene · doi:10.1038/sj.onc.1206595 · Cited by 51 · see citing works

A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma

Goyal, L., Wadlow, R. C., Blaszkowsky, L. S., Wolpin, B. M., Abrams, T. A., McCleary, N. J., Sheehan, S., Sundaram, E., Karol, M. D., Chen, J. L., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0164-8 · Cited by 49 · see citing works

Molecular genetics of human cancer predisposition and progression

Cavenee, W. K., Scrable, H. J., & James, C. D. (1991) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(91)90015-g · Cited by 48 · see citing works

Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53

Zhao, Y., Zhang, C., Yue, X., Li, X., Liu, X. J., Yu, H., Белый, В. А., Yang, Q., Feng, Z., & Hu, W. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.33 · Cited by 42 · see citing works

Mutant p53 protein, master regulator of human malignancies: A report on the Fifth Mutant p53 Workshop

Blandino, G., Deppert, W., Hainaut, P., Levine, A., Lozano, G., Olivier, M., Rotter, V, Wiman, K., & Oren, M. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.148 · Cited by 34 · see citing works

Endogenous Human MDM2-C Is Highly Expressed in Human Cancers and Functions as a p53-Independent Growth Activator

Okoro, D. R., Arva, N. C., Gao, C., Polotskaia, A., Puente, C., Rosso, M., & Bargonetti, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077643 · Cited by 32 · see citing works

Hypoxia, Mn-SOD and H2O2 regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells

Rieber, M., & Strasberg–Rieber, M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.09.003 · Cited by 30 · see citing works

A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis

Yue, X., Zhao, Y., Huang, G. C., Li, J., Zhu, J., Feng, Z., & Hu, W. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.39 · Cited by 30 · see citing works

Expression of p53 Protein Phosphorylated at Serine 20 and Serine 392 in Malignant and Benign Ovarian Neoplasms

Bar, J. K., Saomska, I., Rabczycki, J., et al. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181b70465 · Cited by 28 · see citing works

Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract

Furihata, M., Kurabayashl, A., Matsumoto, M., et al. (2002) · The Journal of Pathology · doi:10.1002/path.1082 · Cited by 26 · see citing works

Stress-Induced Isoforms of MDM2 and MDM4 Correlate with High-Grade Disease and an Altered Splicing Network in Pediatric Rhabdomyosarcoma

Jacob, A. G., O'Brien, D., Singh, R. K., Comiskey, D. F., Littleton, R. M., Mohammad, F., Gladman, J. T., Widmann, M. C., Jeyaraj, S. C., Bolinger, C., et al. (2013) · Neoplasia · doi:10.1593/neo.13286 · Cited by 25 · see citing works

MDM2 Splice Variants and Their Therapeutic Implications

Harris, L. C. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332654 · Cited by 24 · see citing works

Targeting mutant p53 for cancer therapy

Oren, M., Tal, P., & Rotter, V. (2016) · Aging · doi:10.18632/aging.100992 · Cited by 23 · see citing works

Erratum: Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

Alexandrova, E. M., Yallowitz, A. R., Li, D., et al. (2015) · Nature · doi:10.1038/nature15720 · Cited by 4 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

The p53 Pathway in Glioblastoma

Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works

p53 modifications: exquisite decorations of the powerful guardian

Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392 · see citing works

Insights into regulators of p53 acetylation

Nagasaka, M., Miyajima, C., Aoki, H., Aoyama, M., Morishita, D., Inoue, Y., & Hayashi, H. (2022) · Cells · doi:10.3390/cells11233825 · Cited by 45 · see citing works

High efficiency temperature-sensitive amber suppressor strains of Escherichia coli K12

Oeschger, M. P., & Wiprud, G. T. (1980) · Molecular and General Genetics MGG · doi:10.1007/bf00270475 · Cited by 23 · see citing works

Tumorigenesis and cell evolution

Cai, D. (1995) · Medical Hypotheses · doi:10.1016/0306-9877(95)90256-2

Mutant p53 Gain-of-Function in the Spotlight: Are We Suffering a GOF Delusion?

Lane, D. P. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1362 · Cited by 13 · see citing works

[Role of the tumor suppressor ARF in oncogenesis].

Pimkina, I. S., & Ae, D. (2009) · PubMed

Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis.

Solomon, H., Brosh, R., Buganim, Y., & Rotter, V. (2010) · PubMed · Cited by 40 · see citing works